sugammadex News
Most Popular sugammadex Story
FDA rejects Schering-Plough's Bridion
Schering-Plough's stock fell on the surprising news that the FDA rejected Bridion (sugammadex), a treatment to reverse muscle relaxation during general anesthesia. The FDA expressed concern over Read more...
Latest Headlines
- August 1, 2008
- July 30, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
